Jim Cramer Discusses the Moderna Rally and the Impact of FDA Leadership Changes [Yahoo! Finance]
Moderna, Inc. (MRNA)
Last moderna, inc. earnings: 2/26 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
marinabio.com/investor-relations
Company Research
Source: Yahoo! Finance
for the first quarter . Cramer highlighted the bullish environment around the stock, as he said: Finally, aside from the data center plays and the commodity plays, there's a one-off in the top 10 list, and that's Moderna, up 72% in the first quarter, the sixth best performer in the S&P. Moderna cleaned up during the pandemic, but then spent years lost in the wilderness as they never came up with anything that could replace the COVID vaccine. Lately, though, the stock's been breaking out, settling key lawsuits that have been an overhang, getting its new flu vaccine reviewed by a previously hostile FDA. And then last month, we learned that Dr. Vinay Prasad, that's the vaccine skeptic who RFK Jr put in charge of the vaccines at the FDA, he'll be leaving at the end of this month. Great news for Moderna, which is primarily a vaccine company. Photo by Ian Hutchinson on Unsplash Moderna, Inc. (NASDAQ:MRNA) makes mRNA medicines and vaccines to protect against illnesses like the flu, COV
Show less
Read more
Impact Snapshot
Event Time:
MRNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRNA alerts
High impacting Moderna, Inc. news events
Weekly update
A roundup of the hottest topics
MRNA
News
- Moderna (MRNA) had its price target raised by Barclays PLC from $25.00 to $48.00. They now have an "equal weight" rating on the stock.MarketBeat
- Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RSPH)? [Yahoo! Finance]Yahoo! Finance
- Looking for Small-Cap Value? Consider These 2 ETFs [Yahoo! Finance]Yahoo! Finance
- The 20 stocks hedge funds love to short [Seeking Alpha]Seeking Alpha
- Spikevax (Moderna) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F [Yahoo! Finance]Yahoo! Finance
MRNA
Earnings
- 2/13/26 - Beat
MRNA
Sec Filings
- 4/6/26 - Form 4
- 3/27/26 - Form SCHEDULE
- 3/16/26 - Form DEFA14A
- MRNA's page on the SEC website